Omega-3 Index
Omega-3 Index (RBC EPA + DHA %)
What it is
The omega-3 index measures the content of two long-chain omega-3 polyunsaturated fatty acids — eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) — in the membranes of red blood cells, expressed as a percentage of total fatty acids. Measuring in erythrocyte membranes, rather than plasma, is the defining distinction. Plasma omega-3 concentrations reflect recent dietary intake over hours to days — they fluctuate with a single fish meal and are not representative of sustained omega-3 status. Red blood cell membranes, by contrast, incorporate fatty acids during erythropoiesis and reflect the ambient fatty acid environment over the lifespan of the RBC — approximately 120 days. This makes the omega-3 index an integrated, stable biomarker of omega-3 status, analogous to HbA1c as an integrated measure of glucose exposure rather than a single glucose reading. EPA and DHA are derived from oily fish, marine algae, and supplementation; they cannot be synthesised in adequate quantities from the short-chain alpha-linolenic acid (ALA) found in plant sources, making direct dietary or supplemental intake the only reliable route to optimal status.
Why we measure it
The omega-3 index was proposed as a cardiovascular risk factor by Harris and Von Schacky in a 2004 paper in Preventive Medicine, reviewing prospective epidemiological evidence and mechanistic data to propose a risk classification based on erythrocyte EPA + DHA content. Subsequent prospective studies consistently found that low omega-3 index values predicted sudden cardiac death, fatal myocardial infarction, and all-cause cardiovascular mortality. The mechanisms are multiple: EPA and DHA are precursors to specialised pro-resolving lipid mediators (resolvins and protectins) that actively resolve inflammation; they reduce hepatic triglyceride synthesis; they stabilise cardiomyocyte membrane electrophysiology and reduce arrhythmia risk; they improve endothelial function; and they reduce platelet aggregation. The therapeutic implications were established most definitively in the REDUCE-IT trial, published in the New England Journal of Medicine in 2018, which randomised 8,179 high-risk patients on statin therapy to 4g/day of icosapentaenoic acid (EPA alone) and observed a 25% relative reduction in major adverse cardiovascular events — including a 20% reduction in cardiovascular death — at a median follow-up of 4.9 years. Critically, the REDUCE-IT population entered the trial with a mean omega-3 index of approximately 3–4%, well below the low-risk target of 8% — consistent with the population-level under-supplementation that regular testing is designed to detect and correct.
Why every 6 months
Since the omega-3 index reflects the past 120 days of RBC fatty acid incorporation, the six-month testing interval provides approximately 1.5 complete RBC membrane cycles per measurement period — sufficient to confirm that a dietary or supplementation change has achieved a stable new equilibrium. Fish oil supplementation produces a measurable increase in the omega-3 index within 8–12 weeks, reaching a new steady state by approximately 16 weeks. Six-monthly testing can confirm that a supplementation dose is maintaining the target range across different seasons and dietary patterns, and detect drift when supplementation adherence falls or dietary intake decreases.
What movement means
Harris and Von Schacky's 2004 classification, which remains the most widely used clinical framework, defines high risk as omega-3 index below 4%, intermediate risk as 4–8%, and low risk — the target — as ≥ 8%. In Western populations consuming low-fish diets without supplementation, mean omega-3 index values of 4–5% are common, placing most individuals in the intermediate or high-risk category. Japanese populations consuming traditional high-fish diets consistently achieve omega-3 index values of 9–11%, consistent with their substantially lower rates of coronary heart disease death.
High Risk
< 4%
High-risk category as defined by Harris & Von Schacky. Associated with substantially elevated risk of sudden cardiac death and major cardiovascular events in prospective studies. Corresponds to the range typically seen in Western populations with low oily fish intake and no supplementation.
Harris WS, von Schacky C, Preventive Medicine, 2004 — doi:10.1016/j.ypmed.2004.03.012
Intermediate Risk
4 – 8%
Intermediate-risk category. Cardiovascular risk is elevated relative to the low-risk target. Supplementation with EPA and DHA produces measurable index improvements within 8–16 weeks. Most adults supplementing with 1–2g EPA+DHA daily will achieve the upper portion of this range.
Harris WS, von Schacky C, Preventive Medicine, 2004 — doi:10.1016/j.ypmed.2004.03.012
Low Risk (Target)
≥ 8%
Low-risk category and the protocol target. Consistent with the omega-3 status seen in Japanese populations with low rates of coronary heart disease mortality. Typically achievable with regular oily fish consumption (two to four servings per week) or equivalent supplementation of 2–4g EPA+DHA daily.
Harris WS, von Schacky C, Preventive Medicine, 2004 — doi:10.1016/j.ypmed.2004.03.012
In the protocol
References
- 1.
Harris WS, von Schacky C. “The Omega-3 Index: A New Risk Factor for Death from Coronary Heart Disease?.” Preventive Medicine. 2004.
- 2.
Bhatt DL, Steg PG, Miller M, et al.. “Cardiovascular Risk Reduction with Icosapentaenoic Acid for Hypertriglyceridemia.” New England Journal of Medicine. 2018.
- 3.
Albert CM, Campos H, Stampfer MJ, et al.. “Blood Levels of Long-Chain n-3 Fatty Acids and the Risk of Sudden Death.” New England Journal of Medicine. 2002.
- 4.
Mozaffarian D, Rimm EB. “Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits.” JAMA. 2006.